tetano
Editor, Senior Moderator
BMC Med
. 2022 May 4;20(1):181.
doi: 10.1186/s12916-022-02383-4.
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
Chang Kyung Kang[SUP] #[/SUP][SUP] 1 [/SUP], Hyun Mu Shin[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Pyoeng Gyun Choe[SUP] #[/SUP][SUP] 1 [/SUP], Jiyoung Park[SUP] 5 [/SUP], Jisu Hong[SUP] 2 3 5 [/SUP], Jung Seon Seo[SUP] 6 [/SUP], Yung Hie Lee[SUP] 6 [/SUP], Euijin Chang[SUP] 1 7 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Minji Kim[SUP] 2 3 8 [/SUP], Yong-Woo Kim[SUP] 4 [/SUP], Hang-Rae Kim[SUP] 2 3 4 8 9 [/SUP], Chang-Han Lee[SUP] 10 11 12 [/SUP], Jun-Young Seo[SUP] 13 [/SUP], Wan Beom Park[SUP] 14 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
Abstract
Background: Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic.
Methods: We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern.
Results: A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses.
Conclusion: One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis.
Keywords: COVID-19; Immune response; SARS-CoV-2; Vaccination; mRNA.
. 2022 May 4;20(1):181.
doi: 10.1186/s12916-022-02383-4.
Broad humoral and cellular immunity elicited by one-dose mRNA vaccination 18 months after SARS-CoV-2 infection
Chang Kyung Kang[SUP] #[/SUP][SUP] 1 [/SUP], Hyun Mu Shin[SUP] #[/SUP][SUP] 2 3 4 [/SUP], Pyoeng Gyun Choe[SUP] #[/SUP][SUP] 1 [/SUP], Jiyoung Park[SUP] 5 [/SUP], Jisu Hong[SUP] 2 3 5 [/SUP], Jung Seon Seo[SUP] 6 [/SUP], Yung Hie Lee[SUP] 6 [/SUP], Euijin Chang[SUP] 1 7 [/SUP], Nam Joong Kim[SUP] 1 [/SUP], Minji Kim[SUP] 2 3 8 [/SUP], Yong-Woo Kim[SUP] 4 [/SUP], Hang-Rae Kim[SUP] 2 3 4 8 9 [/SUP], Chang-Han Lee[SUP] 10 11 12 [/SUP], Jun-Young Seo[SUP] 13 [/SUP], Wan Beom Park[SUP] 14 [/SUP], Myoung-Don Oh[SUP] 1 [/SUP]
Affiliations
- PMID: 35508998
- DOI: 10.1186/s12916-022-02383-4
Abstract
Background: Practical guidance is needed regarding the vaccination of coronavirus disease 2019 (COVID-19) convalescent individuals in resource-limited countries. It includes the number of vaccine doses that should be given to unvaccinated patients who experienced COVID-19 early in the pandemic.
Methods: We recruited COVID-19 convalescent individuals who received one or two doses of an mRNA vaccine within 6 or around 18 months after a diagnosis of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection. Their samples were assessed for IgG-binding or neutralizing activity and cell-mediated immune responses against SARS-CoV-2 wild-type and variants of concern.
Results: A total of 43 COVID-19 convalescent individuals were analyzed in the present study. The results showed that humoral and cellular immune responses against SARS-CoV-2 wild-type and variants of concern, including the Omicron variant, were comparable among patients vaccinated within 6 versus around 18 months. A second dose of vaccine did not significantly increase immune responses.
Conclusion: One dose of mRNA vaccine should be considered sufficient to elicit a broad immune response even around 18 months after a COVID-19 diagnosis.
Keywords: COVID-19; Immune response; SARS-CoV-2; Vaccination; mRNA.